Letter | Published:

Diabetic hyperglycaemia activates CaMKII and arrhythmias by O-linked glycosylation

Nature volume 502, pages 372376 (17 October 2013) | Download Citation


Ca2+/calmodulin-dependent protein kinase II (CaMKII) is an enzyme with important regulatory functions in the heart and brain, and its chronic activation can be pathological. CaMKII activation is seen in heart failure, and can directly induce pathological changes in ion channels, Ca2+ handling and gene transcription1. Here, in human, rat and mouse, we identify a novel mechanism linking CaMKII and hyperglycaemic signalling in diabetes mellitus, which is a key risk factor for heart2 and neurodegenerative diseases3,4. Acute hyperglycaemia causes covalent modification of CaMKII by O-linked N-acetylglucosamine (O-GlcNAc). O-GlcNAc modification of CaMKII at Ser 279 activates CaMKII autonomously, creating molecular memory even after Ca2+ concentration declines. O-GlcNAc-modified CaMKII is increased in the heart and brain of diabetic humans and rats. In cardiomyocytes, increased glucose concentration significantly enhances CaMKII-dependent activation of spontaneous sarcoplasmic reticulum Ca2+ release events that can contribute to cardiac mechanical dysfunction and arrhythmias1. These effects were prevented by pharmacological inhibition of O-GlcNAc signalling or genetic ablation of CaMKIIδ. In intact perfused hearts, arrhythmias were aggravated by increased glucose concentration through O-GlcNAc- and CaMKII-dependent pathways. In diabetic animals, acute blockade of O-GlcNAc inhibited arrhythmogenesis. Thus, O-GlcNAc modification of CaMKII is a novel signalling event in pathways that may contribute critically to cardiac and neuronal pathophysiology in diabetes and other diseases.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from $8.99

All prices are NET prices.


  1. 1.

    , & CaMKII in myocardial hypertrophy and heart failure. J. Mol. Cell. Cardiol. 51, 468–473 (2011)

  2. 2.

    et al. Heart disease and stroke statistics—2011 update: a report from the American Heart Association. Circulation 123, e18–e209 (2011)

  3. 3.

    Therapy Insight: type 2 diabetes mellitus and the risk of late-onset Alzheimer’s disease. Nature Clin. Pract. Neurol. 2, 159–166 (2006)

  4. 4.

    , , , & Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol. 5, 64–74 (2006)

  5. 5.

    , , , & Structure of the autoinhibited kinase domain of CaMKII and SAXS analysis of the holoenzyme. Cell 123, 849–860 (2005)

  6. 6.

    et al. Visualization of synaptic Ca2+/calmodulin-dependent protein kinase II activity in living neurons. J. Neurosci. 25, 3107–3112 (2005)

  7. 7.

    , , , & Fluorescence resonance energy transfer-based sensor Camui provides new insight into mechanisms of calcium/calmodulin-dependent protein kinase II activation in intact cardiomyocytes. Circ. Res. 109, 729–738 (2011)

  8. 8.

    & Structure-–function of the multifunctional Ca2+/calmodulin-dependent protein kinase II. Biochem. J. 364, 593–611 (2002)

  9. 9.

    et al. A dynamic pathway for calcium-independent activation of CaMKII by methionine oxidation. Cell 133, 462–474 (2008)

  10. 10.

    , & Cycling of O-linked β-N-acetylglucosamine on nucleocytoplasmic proteins. Nature 446, 1017–1022 (2007)

  11. 11.

    & The role of protein O-linked β-N-acetylglucosamine in mediating cardiac stress responses. Biochim Biophys Acta. 1800, 57–66 (2010)

  12. 12.

    , , , & Modification of STIM1 by O-linked N-acetylglucosamine (O-GlcNAc) attenuates store-operated calcium entry in neonatal cardiomyocytes. J. Biol. Chem. 287, 39094–39106 (2012)

  13. 13.

    , , , & Regulation of the inositol 1,4,5-trisphosphate receptor type I by O-GlcNAc glycosylation. J. Neurosci. 27, 13813–13821 (2007)

  14. 14.

    , , , & Isoform-specific regulation of the inositol 1,4,5-trisphosphate receptor by O-linked glycosylation. J. Biol. Chem. 286, 15688–15697 (2011)

  15. 15.

    , , & Regulation of calcium/calmodulin-dependent kinase IV by O-GlcNAc modification. J. Biol. Chem. 284, 21327–21337 (2009)

  16. 16.

    , & Dynamic glycosylation of nuclear and cytosolic proteins. Cloning and characterization of a unique O-GlcNAc transferase with multiple tetratricopeptide repeats. J. Biol. Chem. 272, 9308–9315 (1997)

  17. 17.

    , , , & Dynamic O-glycosylation of nuclear and cytosolic proteins: cloning and characterization of a neutral, cytosolic β-N-acetylglucosaminidase from human brain. J. Biol. Chem. 276, 9838–9845 (2001)

  18. 18.

    , , , & Identification and expression of δ-isoforms of the multifunctional Ca2+/calmodulin-dependent protein kinase in failing and nonfailing human myocardium. Circ. Res. 84, 713–721 (1999)

  19. 19.

    et al. The δC isoform of CaMKII is activated in cardiac hypertrophy and induces dilated cardiomyopathy and heart failure. Circ. Res. 92, 912–919 (2003)

  20. 20.

    et al. Requirement for Ca2+/calmodulin-dependent kinase II in the transition from pressure overload-induced cardiac hypertrophy to heart failure in mice. J. Clin. Invest. 119, 1230–1240 (2009)

  21. 21.

    et al. Diabetes due to a progressive defect in β-cell mass in rats transgenic for human islet amyloid polypeptide (HIP Rat): a new model for type 2 diabetes. Diabetes 53, 1509–1516 (2004)

  22. 22.

    et al. Increased sarcoplasmic reticulum calcium leak but unaltered contractility by acute CaMKII overexpression in isolated rabbit cardiac myocytes. Circ. Res. 98, 235–244 (2006)

  23. 23.

    , , & Ca2+/calmodulin-dependent protein kinase II phosphorylation of ryanodine receptor does affect calcium sparks in mouse ventricular myocytes. Circ. Res. 99, 398–406 (2006)

  24. 24.

    et al. Angiotensin II induces afterdepolarizations via reactive oxygen species and calmodulin kinase II signaling. J. Mol. Cell. Cardiol. 50, 128–136 (2011)

  25. 25.

    et al. Low serum magnesium concentrations are associated with a high prevalence of premature ventricular complexes in obese adults with type 2 diabetes. Cardiovasc. Diabetol. 11, 23 (2012)

  26. 26.

    et al. Diabetes increases mortality after myocardial infarction by oxidizing CaMKII. J. Clin. Invest. 123, 1262–1274 (2013)

  27. 27.

    & Excitotoxic neuroprotection and vulnerability with CaMKII inhibition. Mol. Cell. Neurosci. 46, 720–730 (2011)

  28. 28.

    et al. Hyperamylinemia contributes to cardiac dysfunction in obesity and diabetes: a study in humans and rats. Circ. Res. 110, 598–608 (2012)

  29. 29.

    et al. Ryanodine receptor phosphorylation by calcium/calmodulin-dependent protein kinase II promotes life-threatening ventricular arrhythmias in mice with heart failure. Circulation 122, 2669–2679 (2010)

  30. 30.

    & Quantification of arrhythmias using scoring systems: an examination of seven scores in an in vivo model of regional myocardial ischaemia. Cardiovasc. Res. 22, 656–665 (1988)

Download references


We thank Y. Hayashi for providing initial Camui samples, H. Schulman for helpful discussions, K. Margulies for human heart samples, L.-W. Jin, M. Melara and the University of California, Davis Alzheimer’s Disease Center (NIH-P30AG010129) for human brain samples, and J. H. Brown for providing CaMKIIδ-knockout mice. We thank Pfizer, Inc. for the gift of a breeding pair of HIP rats to F.D. This work was supported by American Heart Association 13SDG14680072 and National Institutes of Health (NIH) T32HL86350 (J.R.E.); NIH 1R01HL118474-01A1, NSF CBET 1133339, ADA 1-13-IN-70 and AHA 13GRNT16470034 (F.D.); NIH R01DK61671 and P01HL107153 (G.W.H.); NIH R01HL111600 (C.M.R.); NIH P01HL080101, R37HL30077 and Fondation Leducq Transatlantic CaMKII Alliance (D.M.B.). G.W.H. receives a share of royalty on sales of the CTD 110.6 antibody, which are managed by Johns Hopkins University.

Author information


  1. Department of Pharmacology, University of California, Davis, 451 Health Sciences Drive, Davis, California 95616, USA

    • Jeffrey R. Erickson
    • , Laetitia Pereira
    • , Lianguo Wang
    • , Amanda Ferguson
    • , Khanha Dao
    • , Florin Despa
    • , Crystal M. Ripplinger
    •  & Donald M. Bers
  2. Department of Physiology, University of Otago, Dunedin 9054, New Zealand

    • Jeffrey R. Erickson
  3. Department of Biological Chemistry, Johns Hopkins University School of Medicine, 725 North Wolfe Street, Baltimore, Maryland 21205, USA

    • Guanghui Han
    • , Ronald J. Copeland
    •  & Gerald W. Hart
  4. Department of Molecular and Biomedical Pharmacology, University of Kentucky, 900 S. Limestone, Lexington, Kentucky 40536, USA

    • Florin Despa


  1. Search for Jeffrey R. Erickson in:

  2. Search for Laetitia Pereira in:

  3. Search for Lianguo Wang in:

  4. Search for Guanghui Han in:

  5. Search for Amanda Ferguson in:

  6. Search for Khanha Dao in:

  7. Search for Ronald J. Copeland in:

  8. Search for Florin Despa in:

  9. Search for Gerald W. Hart in:

  10. Search for Crystal M. Ripplinger in:

  11. Search for Donald M. Bers in:


J.R.E. and D.M.B. conceived the project. J.R.E. and L.P. carried out most of the experiments. L.W. and C.M.R. conducted optical mapping and in vivo ECG experiments and analysis. G.H., R.J.C. and G.W.H. conducted ETD-MS analysis. A.F. and K.D. generated constructs, performed animal surgeries, and participated in data analysis. F.D. contributed diabetic rats and some analysis therewith. J.R.E. and D.M.B. wrote the manuscript, with assistance from the other authors.

Competing interests

The authors declare no competing financial interests.

Corresponding author

Correspondence to Donald M. Bers.

Extended data

About this article

Publication history







By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.